BioCryst Achieves First-Ever Full-Year Profitability, Reports Strong ORLADEYO Growth, and Positive Phase 3 Data for Navenibart
BCRX sits 31% above its 52-week low of $6.
Summary
BioCryst Pharmaceuticals reported its first full year of GAAP profitability in 2025, driven by strong ORLADEYO revenue growth, and announced positive interim Phase 3 results for navenibart, a key asset from its recent Astria Therapeutics acquisition.
Key Events · Earnings and Guidance · BCRX
-
Achieved First-Ever Full-Year GAAP Profitability
Reported net income of $263.8 million for 2025, a historic milestone for the company, marking its first full year of GAAP profitability.
-
Strong ORLADEYO Revenue Growth
Full-year 2025 ORLADEYO net revenue reached $601.8 million, a 38% year-over-year increase, exceeding preliminary guidance.
-
FDA Approval for Pediatric ORLADEYO
Received FDA approval for an oral pellet formulation of ORLADEYO for HAE patients aged 2 to <12 years, expanding the drug's market.
-
Highly Positive Navenibart Phase 3 Data
Interim results from the ALPHA-SOLAR trial for navenibart (acquired from Astria Therapeutics) showed robust HAE attack suppression with over 90% reduction, significantly de-risking this late-stage pipeline asset.
Analysis · BCRX · Life Sciences
This 8-K marks a significant turning point for BioCryst, as the company achieved full-year GAAP profitability for the first time in its history, reporting a net income of $263.8 million for 2025. This financial milestone is underpinned by robust performance of its flagship drug, ORLADEYO, which saw net revenue reach $601.8 million, exceeding prior preliminary estimates. Furthermore, the company received FDA approval for a pediatric formulation of ORLADEYO, expanding its market reach. A major highlight is the highly positive interim Phase 3 results for navenibart, acquired through the Astria Therapeutics acquisition. The ALPHA-SOLAR trial demonstrated sustained, robust HAE attack suppression with over 90% reduction, significantly de-risking this pipeline asset and bolstering BioCryst's long-term growth trajectory in hereditary angioedema. The maintained 2026 revenue guidance further signals management's confidence. Investors should view this filing as a strong validation of BioCryst's strategy and execution, with both current product performance and future pipeline prospects showing significant strength.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.2% of the 326 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCRX was trading at $7.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $6.00 to $11.31. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.